Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

COVID‐19 in multiple sclerosis patients: susceptibility, severity risk factors and serological response
Ana Zabalza, Simón Cárdenas‐Robledo, Paula Tagliani, et al.
European Journal of Neurology (2020) Vol. 28, Iss. 10, pp. 3384-3395
Closed Access | Times Cited: 129

Showing 1-25 of 129 citing articles:

Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy
Sokratis A. Apostolidis, Mihir Kakara, Mark M. Painter, et al.
Nature Medicine (2021) Vol. 27, Iss. 11, pp. 1990-2001
Open Access | Times Cited: 474
Robust T-Cell Responses in Anti-CD20-Treated Patients Following COVID-19 Vaccination: A Prospective Cohort Study
Natacha Madelon, Kim Lauper, Gautier Bréville, et al.
Clinical Infectious Diseases (2021) Vol. 75, Iss. 1, pp. e1037-e1045
Open Access | Times Cited: 108
DMTs and Covid‐19 severity in MS: a pooled analysis from Italy and France
Maria Pia Sormani, Marco Salvetti, Pierre Labauge, et al.
Annals of Clinical and Translational Neurology (2021) Vol. 8, Iss. 8, pp. 1738-1744
Open Access | Times Cited: 103
Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic
de Sèze, Élisabeth Maillart, Antoine Guéguen, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 63
Multiple sclerosis and COVID-19: interactions and unresolved issues
Ana Zabalza, Alan J. Thompson, Dalia Rotstein, et al.
The Lancet Neurology (2025) Vol. 24, Iss. 4, pp. 361-370
Closed Access | Times Cited: 1
Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19
Leoni Rolfes, Marc Pawlitzki, Steffen Pfeuffer, et al.
Neurology Neuroimmunology & Neuroinflammation (2021) Vol. 8, Iss. 5
Open Access | Times Cited: 86
Anti-CD20 therapies decrease humoral immune response to SARS-CoV-2 in patients with multiple sclerosis or neuromyelitis optica spectrum disorders
Céline Louapre, Michella Ibrahim, Élisabeth Maillart, et al.
Journal of Neurology Neurosurgery & Psychiatry (2021) Vol. 93, Iss. 1, pp. 24-31
Open Access | Times Cited: 80
Administration of COVID-19 vaccines in immunocompromised patients
Manica Negahdaripour, Mojtaba Shafiekhani, Seyed Mohammad Iman Moezzi, et al.
International Immunopharmacology (2021) Vol. 99, pp. 108021-108021
Open Access | Times Cited: 72
Vaccination and immunotherapies in neuroimmunological diseases
Alexander Winkelmann, Micha Loebermann, Michael Barnett, et al.
Nature Reviews Neurology (2022) Vol. 18, Iss. 5, pp. 289-306
Open Access | Times Cited: 42
Case report: Sotrovimab, remdesivir and nirmatrelvir/ritonavir combination as salvage treatment option in two immunocompromised patients hospitalized for COVID-19
Federico Baldi, Chiara Dentone, Małgorzata Mikulska, et al.
Frontiers in Medicine (2023) Vol. 9
Open Access | Times Cited: 29
Obesity and Multiple Sclerosis—A Multifaceted Association
Thomas Gabriel Schreiner, Tudor-Marcel Genes
Journal of Clinical Medicine (2021) Vol. 10, Iss. 12, pp. 2689-2689
Open Access | Times Cited: 54
SARS-CoV-2 Antibodies in Adult Patients With Multiple Sclerosis in the Amsterdam MS Cohort
Zoé L. E. van Kempen, Eva Strijbis, Marissa M. C. T. Al, et al.
JAMA Neurology (2021) Vol. 78, Iss. 7, pp. 880-880
Open Access | Times Cited: 48
Update on the management of multiple sclerosis during the COVID-19 pandemic and post pandemic: An international consensus statement
Saúl Reyes, Anthony L. Cunningham, Tomáš Kalinčík, et al.
Journal of Neuroimmunology (2021) Vol. 357, pp. 577627-577627
Open Access | Times Cited: 47
SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study
Maria Pia Sormani, Irene Schiavetti, Doriana Landi, et al.
Multiple Sclerosis Journal (2021) Vol. 28, Iss. 7, pp. 1034-1040
Open Access | Times Cited: 47
Multiple Sclerosis and SARS-CoV-2: Has the Interplay Started?
Gianmarco Bellucci, Virginia Rinaldi, Maria Chiara Buscarinu, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 45
The prevalence of COVID-19 infection in patients with multiple sclerosis (MS): a systematic review and meta-analysis
Abdorreza Naser Moghadasi, Omid Mirmosayyeb, Mahdi Barzegar, et al.
Neurological Sciences (2021) Vol. 42, Iss. 8, pp. 3093-3099
Open Access | Times Cited: 41
Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial
Bruce Cree, Krzysztof Selmaj, Lawrence Steinman, et al.
Multiple Sclerosis Journal (2022) Vol. 28, Iss. 12, pp. 1944-1962
Open Access | Times Cited: 31
Secondary hypogammaglobulinemia in patients with multiple sclerosis on anti-CD20 therapy: Pathogenesis, risk of infection, and disease management
Enrique Álvarez, Erin E. Longbrake, Kottil Rammohan, et al.
Multiple Sclerosis and Related Disorders (2023) Vol. 79, pp. 105009-105009
Open Access | Times Cited: 16
Hypogammaglobulinemia and infections in patients with multiple sclerosis treated with anti-CD20 treatments: a systematic review and meta-analysis of 19,139 multiple sclerosis patients
Anas Elgenidy, Nagham Nader Abdelhalim, Mohammed Al-mahdi Al-kurdi, et al.
Frontiers in Neurology (2024) Vol. 15
Open Access | Times Cited: 5
Comparing the efficacy and safety of extended vs standard dosing of ocrelizumab in MS: A systemic review and meta-analysis.
Mirza Mehmood Ali Baig, Fatima Zulfiqar Siddiqui, Anusha Ashkar, et al.
Multiple Sclerosis and Related Disorders (2025) Vol. 94, pp. 106257-106257
Closed Access
Outcome of COVID-19 in patients with idiopathic inflammatory myopathy during the Omicron wave in China: A longitudinal observational study
Ying Li, Xiaolan Tian, Chao Sun, et al.
PLoS ONE (2025) Vol. 20, Iss. 2, pp. e0317319-e0317319
Open Access
Development of humoral and cellular immunological memory against SARS-CoV-2 despite B cell depleting treatment in multiple sclerosis
Klara Asplund Högelin, Nicolas Ruffin, Elisa Pin, et al.
iScience (2021) Vol. 24, Iss. 9, pp. 103078-103078
Open Access | Times Cited: 39
Altered cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy
Sokratis A. Apostolidis, Mihir Kakara, Mark M. Painter, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 37
Vaccine Considerations for Multiple Sclerosis in the COVID-19 Era
Patricia K. Coyle, Anne R. Gocke, Megan Vignos, et al.
Advances in Therapy (2021) Vol. 38, Iss. 7, pp. 3550-3588
Open Access | Times Cited: 32
Multiple Sclerosis, Disease-Modifying Therapies and COVID-19: A Systematic Review on Immune Response and Vaccination Recommendations
Verónica Cabreira, Pedro Abreu, Ricardo Soares-dos-Reis, et al.
Vaccines (2021) Vol. 9, Iss. 7, pp. 773-773
Open Access | Times Cited: 32
Page 1 - Next Page

Scroll to top